Home > Products > Novel inhibitors
Cat. No. Product name CAS No.
DCC2950 Kr-12-a4

Potent antimicrobial peptide against gram-positive and gram-negative bacteria and relatively high LPS-neutralization activity

DCC2951 Kr-25210

Novel enteroviral replication inhibitor through a non-capsid binding mode with EC 50 values of 2.5, 2.2, and 3.7 μM against hRV B14, A21, and A71, respectively, targeting the replication stages in the virus

DCC2952 Kr-31762

Novel KATP channel opener, exerting cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury

DCC2953 Kras(g12c)-in-1

Novel irreversible inhibitor of KRAS(G12C)

DCC2954 Kras4b-in-d14

Novel specific inhibitor of oncogenic KRAS4b signaling, stabilizing the KRAS4b-PDEδ complex and remarkably decreasing tumor size and triggered apoptosis of tumor cells

924249-06-9
DCC2955 Kras4b-pdeδ Stabilizer C19

Novel stabilizer of the KRAS4b-PDEδ complex, decreasing the proliferation of colorectal cancer cells, and increasing apoptosis via decreased activation of oncogenic KRAS4b signaling

1049727-35-6
DCC2956 Krc-108

Novel potent multi-kinase inhibitor, targeting Ron, Flt3 and TrkA as well as c-Met

1146944-35-5
DCC2957 Krc-327

Selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity.

1350612-75-7
DCC2958 Krm-ii-08

Novel potent, non-toxic, blood-brain barrier crossing, α5-GABA A R preferring ligand, enhancing a chloride-anion efflux that induces mitochondrial membrane depolarization and in response, TP53 upregulation and p53, constitutively phosphorylated at S392, c

DCC2959 Krn4884

Potassium channel opener

152802-84-1
DCC2960 Krn-8602 Hydrochloride

Topo II inhibitor, exhibiting cytotoxic effects against tumour cells

131722-57-1
DCC2961 Krp-109

Novel neutrophil elastase (NE) inhibitor, decreasing expression of TGF-ß Signal Related Genes

1275996-50-3
DCC2962 Krp-199

Highly potent and selective antagonist for the AMPA receptors, exhibiting good neuroprotective effects in vivo

221164-28-9
DCC2963 Krp-204

Novel highly selective β3-adrenoceptor agonist being developed for the treatment of diabetes and obesity

220475-76-3
DCC2964 Ks-133

Novel Potent and Selective VIPR2 Antagonist, Counteracting Cognitive Decline in a Mouse Model of Psychiatric Disorders

DCC2965 Ksc-392-150

Novel inhibitor of the permeability transition pore (PTP)

DCC2966 kscm-1

Selective ligand of the sigma-1 receptor

1415247-17-4
DCC2967 Kscm-11

Ligand of the sigma receptor

1415247-16-3
DCC2968 kscm-5

Ligand of the sigma receptor

1415247-18-5
DCC2969 Ksk120

Novel inhibitor of transcriptional activity in Chlamydia trachomatis

1638100-63-6
DCC2970 Ksl-128114

Novel, highly potent, and metabolically stable peptide inhibitor of syntenin, Inhibiting Glioblastoma

DCC2971 Kspa-1

Novel modulator of kinesin spindle protein (KSP)/Eg5, activating KSP-catalyzed ATP hydrolysis in the absence of microtubules yet inhibiting microtubule-stimulated ATP hydrolysis by KSP

264207-32-1
Page 1356 / Total 1557 FirstPrevNextLastGoto